Detail akcie Puma online

Business Summary: Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Puma Biotechnology Inc revenues decreased 3% to $44.8M. Net loss totaled $3.8M vs. income of $3M. Revenues reflect Product Revenue, net decrease of 3% to $42M, Royalty revenue decrease of 2% to $2.9M. Net loss reflects Development and commercialization of innovative products segment loss totaling $3.8M vs. income of $4M.